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ABSTRACT
Objective: The aim of this study was to compare the efficacy and side-effect profile of the typical
antipsychotic haloperidol with that of the atypical antipsychotics risperidone, olanzapine, and
aripiprazole in the management of delirium.
Method: The Memorial Delirium Assessment Scale (MDAS), the Karnofsky Performance
Status (KPS) scale, and a side-effect rating were recorded at baseline (T1), after 2–3 days (T2),
and after 4–7 days (T3). Some 21 cases were case-matched by age, preexisting dementia, and
baseline MDAS scores, and subsequently analyzed.
Results: The baseline characteristics of the medication groups were not different: The mean
age of the patients ranged from 64.0 to 69.6 years, dementia was present in between 23.8 and
28.6%, and baseline MDAS scores were 19.9 (haloperidol), 18.6 (risperidone), 19.4 (olanzapine),
and 18.0 (aripiprazole). The doses of medication at T3 were 5.5 mg haloperidol, 1.3 mg
risperidone, 7.1 mg olanzapine, and 18.3 mg aripiprazole. Over one week, the decline in MDAS
scores between medications was equal, and no differences between individual MDAS scores
existed at T2 or T3. After one week, the MDAS scores were 6.8 (haloperidol), 7.1 (risperidone),
11.7 (olanzapine), and 8.3 (aripiprazole). At T2, delirium resolution occurred in 42.9–52.4% of
cases and at T3 in 61.9–85.7%; no differences in assessments between medications existed.
Recorded side effects were extrapyramidal symptoms (EPSs) in haloperidol- and risperidone-
managed patients (19 and 4.8%, respectively) and sedation with olanzapine (28.6%).
Significance of Results: Haloperidol, risperidone, aripiprazole, and olanzapine were equally
effective in the management of delirium; however, they differed in terms of their side-effect
profile. Extrapyramidal symptoms were most frequently recorded with haloperidol, and
sedation occurred most frequently with olanzapine.
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INTRODUCTION
Delirium is common in the course of hospitalization,
and its incidence varies with the age of the patient
and illness severity (Elie et al., 1998). In the general
hospital setting, the occurrence of deliriummay reach
an average of 30% inmedically ill patients and 40% in
the hospitalized elderly (Bucht et al., 1999; Lipowski,
1989). In addition to interventions such as providing a
safe and supportive environment, the guidelines for
the management of delirium published by the Ameri-
can Psychiatric Association (Trzepacz et al., 1999)
recommend the use of typical antipsychotics, in par-
ticular haloperidol.However,with increasing frequen-
cy, atypical antipsychotics are selected as the initial
somatic intervention for amelioration of the symptoms
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of delirium due to their favorable side-effect profile
(Lonergan et al., 2007; Rea et al., 2007).
The current literature highlights the efficacy and
tolerability of atypical antipsychotics in providing re-
lief from the distressing symptoms of delirium
(Lonergan et al., 2007; Rea et al., 2007). Studies
have not been able to show differences in efficacy
between haloperidol and aripiprazole (Boettger et al.,
2011a), risperidone (Han & Kim, 2004; Kim et al.,
2005; Liu et al., 2004), or olanzapine (Hu et al., 2004;
Skrobik et al., 2004), and between risperidone and
olanzapine (Kim et al., 2010). However, differences in
the side-effect profile have been documented. Haloper-
idol and aripiprazole have been shown to be equally ef-
fective in the management of hypoactive and
hyperactive delirium, but extrapyramidal symptoms
were more common in haloperidol-treated patients
(Boettger et al., 2011a). No differences in efficacy
have been shown between haloperidol and olanzapine,
and both medications caused a substantial rate of side
effects. EPSs were more commonly encountered with
haloperidol in both studies (Hu et al., 2004; Skrobik
et al., 2004). In particular, dystonia was measured in
up to 31.9% of patients managed with haloperidol
and in up to 2.9% of olanzapine-managed patients,
whereas sedation/drowsiness was found in 22.2% of
haloperidol-managed patients and 18.9% of olanza-
pine-managed patients (Hu et al., 2004). Studies com-
paring haloperidol and risperidone (Han&Kim, 2004;
Kim et al., 2005; Liu et al., 2004) have suggested sim-
ilar efficacy for both medications, with response rates
ranging from 58.3 to 75% (haloperidol) and 42 to
77.8% (risperidone). Another study assessing risperi-
done and olanzapine in the management of delirium
found similar response and side-effect rates but con-
cluded that risperidone may result in poorer response
rates in older age populations (Kim et al., 2010). More
recent studies could not find differences among halo-
peridol, risperidone, and olanzapine (Grover et al.,
2011; Yoon et al., 2013).
To date, the literature comparing the typical and
atypical antipsychotics with respect to efficacy and
side effects remains limited and warrants further
expansion. So we performed an analysis of patients
receiving haloperidol, risperidone, olanzapine, and
aripiprazole in the management of delirium in order
to further explore the comparative efficacy and
side-effect profile of these medications.
METHODS
Patients
All patients were recruited from referrals for delir-
ium management to the Memorial Sloan Kettering
Cancer Center (MSKCC) Psychiatry Service from
July to November of 2000 and from July of 2004 to
June of 2006. MSKCC is a 470-bed, private hospital
specializing in the treatment of cancer, averaging
more than 20,000 admissions each year. The consul-
tation-liaison psychiatry service performs on average
more than 2,000 consultations yearly.
Themain inclusioncriterionwasmeeting theDSM–
IV–TR (American Psychiatric Association, 2000) crite-
ria for delirium. Exclusion criteria included patient or
family objections to pharmacological intervention, an
inability to participate with delirium rating measures,
and severe agitation interfering with interviews.
All patients and their families provided verbal
consent to be evaluated and receive antipsychotics
for symptomatic relief of delirium. In patients with
a limited capacity to provide consent, the patient’s
primary caregiver provided verbal consent alongside
the patient’s assent to intervention. All data were ob-
tained from the routine care of patients diagnosed
with delirium and entered into the institutional re-
view board-approved database for subsequent analy-
sis, and a waiver was obtained for the data analysis.
Measurements
Delirium severity was measured with the MDAS, a
10-item, 4-point, clinician-rated scale (Breitbart
et al., 1997). The MDAS items reflect the diagnostic
criteria for delirium in the DSM–IV–TR and assess
disturbance in arousal and level of consciousness,
cognitive functioning such as orientation, memory,
attention, and perception, as well as psychomotor ac-
tivity.MDAS scores greater than 10 identify the pres-
ence of delirium, and MDAS scores of 10 indicate
resolution of delirium in our analysis (Kazmierski
et al., 2008; Lawlor et al., 2000). Categorization of de-
lirium was based on the motoric subtype: hypoactive
or hyperactive (Camus et al., 2000; Meagher et al.,
2000). Additional instruments included the Karnofsky
PerformanceStatus (KPS) scale (Karnofsky&Burche-
nal, 1949) to provide a measure of physical perfor-
mance ability and an abbreviated version of the
Udvalg for Kliniske Undersogelser Side-Effect Rating
Scale (UKU) to record the side effects of the antipsy-
chotics (Lingjaerde et al., 1987).
Procedures
Sociodemographic and medical variables were collect-
ed at the initial assessment (T1). This information in-
cluded age, gender, cancer diagnosis, stage of cancer
(localized, advanced, metastatic, or terminal), current
psychiatric diagnosis, preexistent dementia, presence
of brain metastases, and contributing delirium etiolo-
gies. MDAS and KPS scores were obtained and side-
effect rating performed at initial diagnosis of delirium
(T1) and repeated at 2–3 days (T2) and 4–7 days (T3).
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The psychiatrist providing the initial diagnosis of
delirium decided which antipsychotic to prescribe.
Patients received haloperidol, risperidone, olanza-
pine, or aripiprazole. If the patient’s delirium
worsened as evidenced by clinical observation or
MDAS scores, the current antipsychotic was discon-
tinued and an alternate antipsychotic substituted.
Statistical Analysis
Data analyses were performed with the Statistical
Package for the Social Sciences (SPSS, v. 20) for Win-
dows. Descriptive statistics were performed on the
dataset to characterize the sample sociodemographi-
cally and medically. The primary interest was MDAS
score, and the side-effect profile was secondary. Sep-
arate datasets describing individual medications
were created for comparison of efficacy and side-
effect profile. The t test for independent samples
was employed for data on the interval scale including
age. A MANOVAwas computed for the course of hal-
operidol, risperidone, aripiprazole, and olanzapine
over time, and the between factor was themedication
administered; MDAS scores at baseline, T1, and T2
were set as dependent measures. For multiple relat-
ed measures, such as the course of change in MDAS
scores for single medications, the Friedman test was
utilized, and for multiple independent measures,
such as comparison of MDAS scores at single times,
the Kruskal–Wallis test. Categorical variables, such
as the comparison of delirium resolution rates among
medications, were computed with Pearson’s chi-
square test. For all implemented tests, post hoc, alpha
(a) was adjustedwith theBonferronimethod. The sig-
nificance level for a was set at p, 0.05.
Composition of Sample
The sample size for each medication was determined
by the medication with the lowest number of pa-
tients, which was aripiprazole. The data for haloper-
idol, risperidone, and olanzapine were matched to
the aripiprazole sample based on age, preexisting de-
mentia, initial MDAS scores, and delirium subtype.
RESULTS
Baseline Characteristics of Patients
The age of the patients did not differ between groups
and ranged from 64.0 (haloperidol) to 69.6 years (aripi-
prazole). Gender was evenly distributed, with 38.1%
male (haloperidol and olanzapine) and 47.6% female
patients (risperidoneandaripiprazole). Theprevalence
of preexistent dementia was not different, and was
documented in 23.8% of haloperidol- and risperidone-
managed patients and in 28.6% of aripiprazole- and
olanzapine-managed patients.
Cancer diagnoses and stages were diverse
(Table 1). There were no significant differences be-
tween types of cancer or stages of illness and medica-
tion regimens. The etiologies contributing to
delirium were multifactorial and similar between
medication groups. The most frequent etiologies
were the administration of opioids [81% (risperidone)
to 95.2% (haloperidol)], the administration of cortico-
steroids [33.3% (haloperidol) to 61.9% (risperidone)],
the presence of hypoxia [28.6% (olanzapine) to 52.4%
(risperidone)], current infection [9.5% (aripiprazole)
to 47.6% (risperidone)]. and the presence of central
nervous system (CNS) disease (from 9.5% for halo-
peridol to 33.3% for aripiprazole).
The severity of delirium did not differ at baseline
and ranged from18 to 30 on theMDAS. In the haloper-
idol-managed patients, the mean MDAS score was
19.9, in risperidone-managed 18.6, in aripiprazole-
managed 18.0, and in olanzapine-managed patients
19.5. Hypoactive delirium and hyperactive delirium
were present in 42.9 and 57.1%, respectively.
Management of Delirium with Haloperidol,
Risperidone, Olanzapine, and Aripiprazole
The mean medication doses at T3 were 5.5 mg halo-
peridol, 1.3 mg risperidone, 18.3 mg aripiprazole,
and 7.1 mg olanzapine. MDAS scores decreased in
all medication groups. In haloperidol-managed pa-
tients, MDAS scores were 19.9 at baseline and
decreased to 9.9 at T2 and 6.8 at T3 (Friedman
x
2
¼ 38.30(2), p , 0.001). In risperidone-managed
patients, MDAS scores declined from 18.6 at baseline
to 11.2 at T2 and to 7.1 at T3 (Friedman x2 ¼ 29.95(2),
p , 0.001). Aripiprazole-managed patients had a
baseline MDAS score of 18.0, declining to 10.8 and
8.3 at T2 and T3, respectively (Friedman
x
2
¼ 31.87(2), p , 0.001). In olanzapine-managed
patients, MDAS scores were 19.4 at baseline and
13.8 and 11.7 at T2 and T3 (Friedman:
x
2
¼ 13.23(2), p , 0.01). The decline of MDAS scores
betweenmedications over timewas equal (MANOVA:
Wilks’s lambda 0.04,F(634.4), p , 0.001). As a result,
therewere no differences betweenmedications at any
single observation point during the observation peri-
od (T2, T3) (Kruskal–Wallis, ns). The delirium reso-
lution rates ranged from 42.9% (olanzapine and
risperidone) to 52.4% (aripiprazole) at T2 and from
61.9% (olanzapine) to 85.7% (risperidone) at T3 and
did not differ between medications (Table 2).
Side Effects
Side effects or lack of responsewere encountered in all
medication groups and ranged from 4.8 (risperidone)
Delirium: Typical vs. atypical antipsychotics 1081
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Table 1. Baseline and medical characteristics of patients
Haloperidol (n ¼ 21) Risperidone (n ¼ 21) Aripiprazole (n ¼ 21) Olanzapine (n ¼ 21) Statistics
Age 64.0 (36–79, SD ¼ 11.7) 67.2 (29–84, SD ¼ 12.7) 69.6 (36–85, SD ¼ 11.9) 65.6 (51–84, SD 13.4) t(40) ¼ 1.024, p ¼ 0.312a
Gender (M/F in %) 38.1/61.9 47.6/52.4 47.6/52.4 38.1/61.9 0.778(3), p ¼ 0.886b
Preexistent dementia (in %) 23.8 23.8 28.6 28.6 0.246(3), p ¼ 0.486b
Cancer diagnosis (in %)
Brain 4.8 4.8 19 * 6.462(3), p ¼ 0.154b
Endocrine – 4.8 4.8 * 2.049(3), p ¼ 1.0b
Gastrointestinal 28.6 23.8 23.8 9.5 2.545(3), p ¼ 0.154b
Genitourinary 4.8 – 19 * 9.144(3), p ¼ 0.051b
Gynecological 19 4.8 9.5 * 5.455(3), p ¼ 0.199b
Head and neck 14.3 4.8 14.3 14.3 4.208(3), p ¼ 0.154b
Lung 19 38.1 – 28.6 3.746(3), p ¼ 0.338b
Sarcoma 9.5 – 9.5 * 4.20(3), p ¼ 0.323b
Lymphoma – 4.8 – 14.3 6.30(3), p ¼ 0.186b
Skin – 9.5 – * 6.146(3), p ¼ 0.154b
Breast – – – 9.5 6.146(3), p ¼ 0.241b
Other – 4.8 – 23.8 12.205(3), p ¼ 0.013b
Stage (in %)
Localized 38.1 28.6 38.1 23.8 1.474, p ¼ 0.754b
Advanced 52.4 57.1 47.6 71.4 2.722, p ¼ 0.515b
Terminal 9.5 14.3 14.3 4.8 1.369, p ¼ 0886b
Brain metastases (in %) 4.8 9.5 14.3 23.8 3.661(3), p ¼ 0.381b
Etiologies (in %)
Opioids 95.2 81 90.5 81 2.824(3), p ¼ 0.523b
Corticosteroids 33.3 61.9 52.4 33.3 5.190(3), p ¼ 0.187b
Hypoxia 33.3 52.4 38.1 28.6 2.827(3), p ¼ 0.499b
Infection 23.8 47.6 9.5 28.6 7.843(3), p ¼ 0.061b
CNS disease 9.5 14.3 33.3 23.8 7.386(3), p ¼ 0.070b
Dehydration – 4.8 4.8 4.8 21.367(3), p ¼ 0.047b
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Table 2. Management characteristics of haloperidol, risperidone, aripiprazole and olanzapine
Haloperidol (n ¼ 21) Risperidone (n ¼ 21) Aripiprazole (n ¼ 21) Olanzapine (n ¼ 21) Statistics
Medication dose (in mg)
Baseline (T1) 4.9 (1.5–16, SD ¼ 2.4) 0.9 (0.5–2, SD ¼ 0.4) 15.2 (5–30, SD ¼ 6.22) 3.5 (2.5–10, SD ¼ 1.9) –
T2 5.5 (1.5–16, SD ¼ 3.5) 1.1 (0.5–3, SD ¼ 0.7) 16.0 (10–30, SD ¼ 5.84) 5.2 (2.5–15, SD ¼ 3.1) –
T3 5.5 (1.5–16, SD ¼ 3.5) 1.3 (0.5–3, SD ¼ 0.7) 18.3 (10–30, SD ¼ 6.58) 7.1 (2.5–20, SD ¼ 4.7) –
MDAS scores
Baseline (T1) 19.9 (12–25, SD ¼ 3.4) 18.6 (11–026, SD ¼ 4.5) 18.0 (11–25, SD ¼ 4.3) 19.4 (14–26, SD ¼ 3.8) 2.396(3), p ¼ 0.497a
T2 9.9 (2–21, SD ¼ 5.34) 11.2 (1–24, SD ¼ 5.6) 10.8 (2–23, SD ¼ 10.8) 13.8 (1–26, SD ¼ 7.5) 3.573(3), p ¼ 0.311a
T3 6.8 (1–17, SD ¼ 4.8) 7.1 (1–22, SD ¼ 5.1) 8.3 (1–23, SD ¼ 8.3) 11.7 (1–26), SD ¼ 8.8) 4.140(3), p ¼ 0.249a
Delirium resolution (in %)
T2 47.6 42.9 52.4 42.9 0.526(3), p ¼ 0.964b
T3 76.2 85.7 76.2 61.9 3.238(3), p ¼ 0.418b
Side effects (in %)
Any side effect 19 4.8 9.5 42.9 11.735(3), p ¼ 0.009b
EPS—dystonia 9.5 – – – 3.036(3), p ¼ 0.1.0b
EPS—parkinsonism 19 4.8 – – 12.60(3), p ¼ 0.012b
Sedation – – – 28.6 19.385(3), p ¼ 0.001b
Worsening – – 9.5 14.3 3.802(3), p ¼ 0.661b
Multiple side effects 9.5 – – 14.3 6.30(3), p ¼ 0.186 b
MDAS ¼Memorial Delirium Assessment Scale; EPS ¼ extrapyramidal symptom.
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to 9.5 (aripiprazole), 19 (haloperidol), and 42.9% (olan-
zapine). The administration of olanzapine most fre-
quently caused side effects, followed by haloperidol,
aripiprazole, and risperidone. In particular, haloperi-
dol and also risperidone caused extrapyramidal symp-
toms (19 and 4.8%, respectively). The most commonly
recorded side effect was sedation (28.6% with olanza-
pine). Sedation may have clinical utility in patients
with hyperactive delirium.
DISCUSSION
These findings indicate that the atypical antipsychot-
ics risperidone, aripiprazole, and olanzapine and the
typical antipsychotic haloperidol were equally effec-
tive in the management of the symptoms of delirium.
The side-effect profile, however, was very different. In
particular, haloperidol caused increased rates of
EPSs and olanzapine substantial sedation, while
the administration of risperidone and in particular
aripiprazole caused less adverse to no side effects.
Anumberof studieshavecompared thesafetyandef-
ficacy of haloperidol and risperidone, aripiprazole, and
olanzapine and found similar efficacy in the manage-
ment of delirium. Compared to previous findings, the
dosing of medication was similar: haloperidol
(5.5 mg), risperidone (1.3 mg), aripiprazole (18.3 mg),
and olanzapine (7.1 mg). In previous investigations,
the dosing of risperidone ranged from 0.75 to 1.7 mg
(Han & Kim, 2004; Kim et al., 2005; 2010; Liu et al.,
2004), aripiprazole was administered at 8.9–18.3 mg
(Boettger et al., 2011a), olanzapine at 2.4– 8.2 mg (Hu
et al., 2004; Kim et al., 2010; Skrobik et al., 2004), and
haloperidol doses ranged from 1.7 to 6.5 mg (Boettger
et al., 2011a; Han & Kim, 2004; Hu et al., 2004;
Kim et al., 2005; Liu et al., 2004). The efficacy rates of
medications were similar to previous findings. In
our analysis, 76.2% of haloperidol-managed patients
(58.3–87.5%), 85.2% of risperidone-managed (42–
84.4%), 76.2% of the aripiprazole-managed, and 61.9%
(64.7–82.4%) of the olanzapine-managed patients
achieved delirium resolution.
Side effects were encountered with most medica-
tions, most commonly EPSs and sedation in haloper-
idol- and olanzapine-managed patients (19 and
28.6%, respectively). More extrapyramidal symp-
toms with haloperidol-managed patients have been
known (Boettger et al., 2011a; Hu et al., 2004), and
sedation is a common side effect of management
with olanzapine and has previously been described
in 18.9% of patients. Side effects in patientsmanaged
with aripiprazole and risperidone were less frequent.
The sample in our analysis was evenly distributed.
The patient population did not differ in age, gender,
preexistent dementia, type and stage of cancer, and
etiology. A different recording approach within the
olanzapine cases, categorizing multiple diagnoses
(marked with an asterisk in Table 1) in the category
“other,” increased the number of “other” cancers
artificially.
Patients in this sample were of advanced age,
ranging from 64.0 to 69.6 years, exceeding the age
range documented in other studies. This is not par-
ticularly surprising, as advanced age and comorbid
dementia are among the main risk factors for devel-
oping delirium (Elie et al., 1998). Both advanced
age and comorbid dementia may be associated with
a prolonged and refractory course of delirium
(Boettger et al., 2011b), thus potentially reducing
the response rates in the observation period.
These findings provide further evidence indicating
that haloperidol, risperidone, aripiprazole, and olan-
zapine were similarly efficacious in the management
of delirium, but had different side-effect profile. As a
consequence, the choice of antipsychotic for the man-
agement of deliriummaybe less determined byefficacy
than by side-effect profile, including potentially desir-
able side effects such as sedation.
Although the data collection had strengths—
including the systematic evaluation and documenta-
tion of etiologies contributing to delirium, the case
matching reducing differences between groups, as
well as the observation and recording of side ef-
fects—several important limitations have to be
noted. Our analysis was based on a retrospective
analysis of prospectively collected data. The selection
of antipsychotic intervention was not random or
based on the treating physicians’ preferences. Fur-
thermore, all patients had cancer diagnoses, and
the generalizability of these results to the noncancer
population may perhaps be limited. The use of anti-
psychotics in the management of delirium has not
been approved by the regulatory agencies, and the
use of antipsychotics in elderly patients with demen-
tia carries a black-box warning of increased risk of
death (Jeste et al., 2008; Schneider et al., 2005). All
patients were case-matched to the lowest number of
cases in each group, and the total number of patients
included in the analysis was limited to 21 for each
medication group. As a consequence, further investi-
gations, particularly double-blind, randomly as-
signed, controlled designs of atypical and typical
antipsychotics, are required to confirm these results.
In summary, our analysis provided further results
indicating that the typical antipsychotic haloperidol
and the atypical antipsychotics risperidone, aripi-
prazole, and olanzapine are similarly efficacious in
the management of delirium; however, their side-
effect profiles are different. As a consequence, the
choice of an antipsychotic was less determined by
its efficacy than its side-effect profile, including the
use of atypical instead of typical antipsychotics, and
Boettger et al.1084
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reducing extrapyramidal symptoms, as well as the
potentially desirable side effect of sedation.
CONFLICTS OF INTEREST
The authors state that they have no conflicts of inter-
est to declare.
REFERENCES
American Psychiatric Association (2000). Diagnostic and
statistical manual of mental disorders, 4th ed., Text
Revision (DSM–IV–TR). Washington, DC, American
Psychiatric Association (see esp. pp. 124–127).
Boettger, S., Friedlander, M., Breitbart, W., et al. (2011a).
Aripiprazole and haloperidol in the treatment of
delirium. The Australian and New Zealand Journal of
Psychiatry, 45, 477–482.
Boettger, S., Passik, S. & Breitbart, W. (2011b). Treatment
characteristics of delirium superimposed on dementia.
International Psychogeriatrics, 23, 1671–1676.
Breitbart, W., Rosenfeld, B., Roth, A., et al. (1997). The
Memorial Delirium Assessment Scale. Journal of Pain
and Symptom Management, 13, 128–137.
Bucht, G., Gustafson, Y. & Sandberg, O. (1999). Epidemiol-
ogy of delirium. Dementia and Geriatric Cognitive Dis-
orders, 10, 315–318.
Camus, V., Burtin, B., Simeone, I., et al. (2000). Factor
analysis supports the evidence of existing hyperactive
and hypoactive subtypes of delirium. International
Journal of Geriatric Psychiatry, 15, 313–316.
Elie, M., Cole, M.G., Primeau, F.J., et al. (1998). Delirium
risk factors in elderly hospitalized patients. Journal of
General Internal Medicine, 13, 204–212.
Grover, S., Kumar, V. & Chakrabarti, S. (2011). Compara-
tive efficacy study of haloperidol, olanzapine, and risper-
idone in delirium. Journal of Psychosomatic Research,
71, 277–281.
Han, C.S. &Kim, Y.K. (2004). A double-blind trial of risper-
idone and haloperidol for the treatment of delirium.
Psychosomatics, 45, 297–301.
Hu, H., Deng, W. & Yang, H. (2004). A prospective random
control study comparison of olanzapine and haloperidol
in senile delirium. Chongqing Medical Journal, 8,
1234–1237.
Jeste, D.V., Blazer, D., Casey, D., et al. (2008). ACNP white
paper: Update on use of antipsychotic drugs in elderly
persons with dementia. Neuropsychopharmacology, 33,
957–970.
Karnofsky, D.A. & Burchenal, J.H. (1949). The clinical eval-
uation of chemotherapeutic agents in cancer. In Evalua-
tion of chemotherapeutic agents. C.M. Macleod (ed.),
pp. 191–205. New York: Columbia University Press.
Kazmierski, J., Kowman, M., Banach, M., et al. (2008).
Clinical utility and use of DSM–IVand ICD–10 criteria
and the Memorial Delirium Assessment Scale in estab-
lishing a diagnosis of delirium after cardiac surgery.
Psychosomatics, 49, 73–76.
Kim, J.Y., Jung, I.K., Han, C., et al. (2005). Antipsychotics
and dopamine transporter gene polymorphisms in delir-
iumpatients.Psychiatry andClinical Neurosciences, 59,
183–188.
Kim, S.W., Yoo, J.A., Lee, S.Y., et al. (2010). Risperidone
versus olanzapine for the treatment of delirium.Human
Psychopharmacology, 25, 298–302.
Lawlor, P.G., Nekolaichuk, C., Gagnon, B., et al. (2000).
Clinical utility, factor analysis, and further validation
of the Memorial Delirium Assessment Scale in patients
with advanced cancer: Assessing delirium in advanced
cancer. Cancer, 88, 2859–2867.
Lingjaerde, O., Ahlfors, U.G., Bech, P., et al. (1987).
The UKU side effect rating scale: A new comprehensive
rating scale for psychotropic drugs and a cross-sectional
study of side effects in neuroleptic-treated patients.Acta
Psychiatrica Scandinavica, 334 (Suppl.), 1–100.
Lipowski, Z.J. (1989). Delirium in the elderly patient. The
New England Journal of Medicine, 320, 578–582.
Liu, C.Y., Juang, Y.Y., Liang, H.Y., et al. (2004). Efficacy of
risperidone in treating the hyperactive symptoms of de-
lirium. International Clinical Psychopharmacology, 19,
165–168.
Lonergan, E., Britton, A.M., Luxenberg, J., et al. (2007).
Antipsychotics for delirium. The Cochrane Database of
Systematic Reviews, 18(2), CD005594.
Meagher, D.J., O’Hanlon, D., O’Mahony, E., et al. (2000).
Relationship between symptoms and motoric subtype
of delirium. The Journal of Neuropsychiatry and Clini-
cal Neurosciences, 12, 51–56.
Rea, R.S., Battistone, S., Fong, J.J., et al. (2007). Atypical
antipsychotics versus haloperidol for treatment of delir-
ium in acutely ill patients. Pharmacotherapy, 27,
588–594.
Schneider, L.S., Dagerman, K.S. & Insel, P. (2005). Risk of
death with atypical antipsychotic drug treatment for de-
mentia: Metaanalysis of randomized placebo-controlled
trials. The Journal of the American Medical Associa-
tion, 19(294), 1934–1943.
Skrobik, Y.K., Bergeron, N., Dumont, M., et al. (2004).
Olanzapine vs. haloperidol: Treating delirium in a criti-
cal care setting. Intensive Care Medicine, 30, 444–449.
Trzepacz, P.T., Breitbart, W., Franklin, J., et al. (1999).
Practice guideline for the treatment of patients with de-
lirium: American Psychiatric Association. The Ameri-
can Journal of Psychiatry, 156, 1–20.
Yoon, H.J., Park, K.M., Choi, W.J., et al. (2013). Efficacy
and safety of haloperidol versus atypical antipsychotic
medications in the treatment of delirium. BMC Psychi-
atry, 13, 240.
Delirium: Typical vs. atypical antipsychotics 1085
https://doi.org/10.1017/S1478951514001059
Downloaded from https:/www.cambridge.org/core. University of Basel Library, on 30 May 2017 at 21:46:08, subject to the Cambridge Core terms of use, available at https:/www.cambridge.org/core/terms.
